Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Chariot CEO raises stake

(Sharecast News) - Chariot revealed on Wednesday that chief executive Adonis Pouroulis had acquired 385,682 ordinary shares in the AIM-listed transitional energy company. Pouroulis, who co-founded Chariot, purchased the shares on Tuesday at an average price of 9.0p each, for a total value of £34,711.38.

As of 1625 GMT, Chariot shares were up 3.61% at 9.29p.

Reporting by Iain Gilbert at

Top Director Buys

Chariot Limited (CHAR) Director name: Pouroulis,Adonis Amount purchased: 385,682 @ 9.00p Value: £34,711.38

Jersey Oil And Gas (JOG) Director name: Benitz,Jason Andrew Amount purchased: 14,422 @ 208.00p Value: £29,997.76

(CBX) Director name: Edwards,Michael Amount purchased: 2,500,000 @ 0.42p Value: £10,425.00

Spectris (SXS) Director name: Heath ,Andrew Amount purchased: 4 @ 3,630.67p Value: £145.23

Spectris (SXS) Director name: Harding ,Derek Amount purchased: 4 @ 3,630.67p Value: £145.23

Top Director Sells

Share this article

Related Sharecast Articles

Director dealings: Blue Coast raises stake in Everyman Media
(Sharecast News) - Everyman Media revealed on Thursday that Blue Coast had acquired 50,000 ordinary shares in the AIM-listed cinema group.
Director dealings: Angus Energy CEO ups stake
(Sharecast News) - Angus Energy revealed on Wednesday that chief executive Richard Herbert had acquired 5.0m ordinary shares in the AIM-listed onshore oil and gas development firm.
Director dealings: Abrdn CEO makes share sale
(Sharecast News) - Abrdn revealed on Monday that chief executive Stephen Bird had disposed of 29,942 ordinary shares in the FTSE 250-listed global investment company.
Director dealings: Redx Pharma CEO ups stake
(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stage biopharmaceutical firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.